

INTERCEPT PHARMACEUTICALS, INC.

Form S-8

July 27, 2018

**As filed with the Securities and Exchange Commission on July 27, 2018**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**Intercept Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

**22-3868459**

(State or other jurisdiction (IRS Employer Identification No.)

of incorporation or organization)

**10 Hudson Yards, 37th Floor**

**New York, NY 10001**

(Address of Principal Executive Offices and Zip Code)

**Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan**

(Full title of the plan)

**Ryan T. Sullivan**

**General Counsel and Secretary**

**Intercept Pharmaceuticals, Inc.**

**10 Hudson Yards, 37th Floor**

**New York, NY 10001**

**(646) 747-1000**

(Name, address and telephone number, including area code, of agent for service)

**Copy to:**

**Graham Robinson**

**Skadden, Arps, Slate, Meagher & Flom LLP**

**500 Boylston Street**

**Boston, MA 02116**

**(617) 573-4800**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input checked="" type="checkbox"/>	Accelerated filer <input type="checkbox"/>
Non-accelerated filer <input type="checkbox"/>	Smaller reporting company <input type="checkbox"/>
(Do not check if a smaller reporting company)	Emerging growth company <input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**CALCULATION OF REGISTRATION FEE**

<b>Title of securities to be registered</b>	<b>Amount to be registered<sup>(1)</sup></b>	<b>Proposed maximum offering price per share<sup>(2)</sup></b>	<b>Proposed maximum aggregate offering price<sup>(2)</sup></b>	<b>Amount of registration fee</b>
Common Stock, par value \$0.001 per share (“Common Stock”), reserved for future grant under the Registrant’s 2012 Equity Incentive Plan	1,080,859	\$94.945	\$102,622,157.76	\$12,776.46

Represents (i) 1,010,693 additional shares issuable under the Registrant's 2012 Equity Incentive Plan (the "Plan") by reason of the automatic increase provisions of the Plan and (ii) 70,166 shares underlying certain equity awards previously issued under the Plan that have been forfeited or cancelled. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Plan by reason of any stock split, stock dividend, combination, recapitalization or other similar transaction effected without receipt of consideration that results in an increase in the number of outstanding shares of the Registrant's Common Stock.

Estimated pursuant to Rule 457(h) and Rule 457(c) under the Securities Act, solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Registrant's Common Stock on July 20, 2018, as reported on the Nasdaq Global Select Market.

**EXPLANATORY NOTE**

Intercept Pharmaceuticals, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 1,080,859 shares of its Common Stock, par value \$0.001 per share (the “Common Stock”), issuable to eligible persons under the Registrant’s 2012 Equity Incentive Plan, which shares of Common Stock are in addition to the shares of Common Stock registered on the Registrant’s Registration Statements on Form S-8 filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7, 2012 (File No. 333-184810), April 22, 2013 (File No. 333-188064), August 7, 2015 (File No. 333-206247) and May 10, 2017 (File No. 333-217863).

Pursuant to General Instruction E to Form S-8, the contents of the Registrant’s Registration Statements on Form S-8 filed with the SEC on November 7, 2012 (File No. 333-184810), April 22, 2013 (File No. 333-188064), August 7, 2015 (File No. 333-206247) and May 10, 2017 (File No. 333-217863) are incorporated by reference into this Registration Statement on Form S-8.

**PART II****INFORMATION REQUIRED IN THE REGISTRATION STATEMENT****Item 8. Exhibits.**

<b>Exhibit Number</b>	<b>Exhibit Description</b>	<b>Incorporated herein by reference</b>		
		<b>Form†</b>	<b>Exhibit</b>	<b>Filing Date</b>
<u>4.1</u>	<u>Restated Certificate of Incorporation, as amended</u>	<u>Form 10-Q</u>	<u>3.1</u>	<u>August 9, 2016</u>
<u>4.2</u>	<u>Restated Bylaws</u>	<u>Form 8-K</u>	<u>3.1</u>	<u>February 17, 2016</u>
<u>4.3</u>	<u>Form of Common Stock Certificate</u>	<u>Form S-8<sup>(1)</sup></u>	<u>4.3</u>	<u>November 7, 2012</u>
<u>4.4</u>	<u>Indenture, dated as of July 6, 2016, between the Registrant and U.S. Bank National Association, as trustee</u>	<u>Form 8-K</u>	<u>4.1</u>	<u>July 6, 2016</u>
<u>4.5</u>	<u>First Supplemental Indenture (including the Form of Note), dated as of July 6, 2016, between the Registrant and U.S. Bank National Association, as trustee</u>	<u>Form 8-K</u>	<u>4.2</u>	<u>July 6, 2016</u>

Edgar Filing: INTERCEPT PHARMACEUTICALS, INC. - Form S-8

<u>4.6</u>	<u>Securities Purchase Agreement, dated April 4, 2018, between the Registrant and the purchasers named therein</u>	<u>Form 8-K</u>	<u>10.1</u>	<u>April 10, 2018</u>
<u>5.1*</u>	<u>Opinion of Skadden, Arps, Slate, Meagher &amp; Flom LLP</u>			
<u>23.1*</u>	<u>Consent of Independent Registered Public Accounting Firm</u>			
<u>23.2*</u>	<u>Consent of Skadden, Arps, Slate, Meagher &amp; Flom LLP (contained in Exhibit 5.1 to this Registration Statement on Form S-8)</u>			
<u>24.1*</u>	<u>Power of Attorney (included in signature page of this Registration Statement on Form S-8)</u>			
<u>99.1</u>	<u>Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan</u>	<u>Form S-1<sup>(2)</sup></u>	<u>10.2.1</u>	<u>September 27, 2012</u>

\* Filed herewith.

Unless otherwise specified, the File No. is 001-35668.

(1) Registration Statement on Form S-8 filed by the Registrant, Registration No. 333-184810.

(2) Registration Statement on Form S-1 filed by the Registrant, Registration No. K33-183706.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on July 27, 2018.

INTERCEPT PHARMACEUTICALS, INC.

By: /s/ Mark Pruzanski, M.D.

Name: Mark Pruzanski, M.D.

Title: President and Chief Executive Officer

## POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Pruzanski, M.D. and Sandip Kapadia, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing required or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned could do in person, and hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ Mark Pruzanski, M.D. Mark Pruzanski, M.D.	President, Chief Executive Officer and Director (Principal Executive Officer)	July 27, 2018
/s/ Sandip Kapadia	Chief Financial Officer and Treasurer (Principal	July 27, 2018

Edgar Filing: INTERCEPT PHARMACEUTICALS, INC. - Form S-8

Sandip Kapadia	Financial Officer and Principal Accounting Officer)	
/s/ Paolo Fundarò Paolo Fundarò	Chairman of the Board of Directors	July 27, 2018
/s/ Srinivas Akkaraju, M.D., Ph.D. Srinivas Akkaraju, M.D., Ph.D.	Director	July 27, 2018
/s/ Luca Benatti, Ph.D. Luca Benatti, Ph.D.	Director	July 27, 2018
/s/ Daniel Bradbury Daniel Bradbury	Director	July 27, 2018
/s/ Keith Gottesdiener, M.D. Keith Gottesdiener, M.D.	Director	July 27, 2018
/s/ Nancy Miller-Rich Nancy Miller-Rich	Director	July 27, 2018
/s/ Gino Santini Gino Santini	Director	July 27, 2018
/s/ Glenn Sblendorio Glenn Sblendorio	Director	July 27, 2018
/s/ Daniel Welch Daniel Welch	Director	July 27, 2018

## EXHIBIT INDEX

Exhibit Number	Exhibit Description	Incorporated herein by reference		
		Form†	Exhibit	Filing Date
<u>4.1</u>	<u>Restated Certificate of Incorporation, as amended</u>	<u>Form 10-Q</u>	<u>3.1</u>	<u>August 9, 2016</u>
<u>4.2</u>	<u>Restated Bylaws</u>	<u>Form 8-K</u>	<u>3.1</u>	<u>February 17, 2016</u>
<u>4.3</u>	<u>Form of Common Stock Certificate</u>	<u>Form S-8<sup>(1)</sup></u>	<u>4.3</u>	<u>November 7, 2012</u>
<u>4.4</u>	<u>Indenture, dated as of July 6, 2016, between the Registrant and U.S. Bank National Association, as trustee</u>	<u>Form 8-K</u>	<u>4.1</u>	<u>July 6, 2016</u>
<u>4.5</u>	<u>First Supplemental Indenture (including the Form of Note), dated as of July 6, 2016, between the Registrant and U.S. Bank National Association, as trustee</u>	<u>Form 8-K</u>	<u>4.2</u>	<u>July 6, 2016</u>
<u>4.6</u>	<u>Securities Purchase Agreement, dated April 4, 2018, between the Registrant and the purchasers named therein</u>	<u>Form 8-K</u>	<u>10.1</u>	<u>April 10, 2018</u>
<u>5.1*</u>	<u>Opinion of Skadden, Arps, Slate, Meagher &amp; Flom LLP</u>			
<u>23.1*</u>	<u>Consent of Independent Registered Public Accounting Firm</u>			
<u>23.2*</u>	<u>Consent of Skadden, Arps, Slate, Meagher &amp; Flom LLP (contained in Exhibit 5.1 to this Registration Statement on Form S-8)</u>			
<u>24.1*</u>	<u>Power of Attorney (included in signature page of this Registration Statement on Form S-8)</u>			
<u>99.1</u>	<u>Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan</u>	<u>Form S-1<sup>(2)</sup></u>	<u>10.2.1</u>	<u>September 27, 2012</u>

\* Filed herewith.

† Unless otherwise specified, the File No. is 001-35668.

(1) Registration Statement on Form S-8 filed by the Registrant, Registration No. 333-184810.

(2) Registration Statement on Form S-1 filed by the Registrant, Registration No. K33-183706.